Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 9
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity.
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, Richer JK. Kuo LW, et al. Cancer Res Commun. 2024 Oct 1;4(10):2699-2713. doi: 10.1158/2767-9764.CRC-24-0272. Cancer Res Commun. 2024. PMID: 39311710 Free PMC article.
The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma.
Van Kleunen L, Ahmadian M, Post MD, Wolsky RJ, Rickert C, Jordan K, Hu J, Richer JK, Marjon NA, Behbakht K, Sikora MJ, Bitler BG, Clauset A. Van Kleunen L, et al. bioRxiv [Preprint]. 2024 Jan 29:2024.01.26.577350. doi: 10.1101/2024.01.26.577350. bioRxiv. 2024. Update in: Cancer Immunol Res. 2024 Nov 4;12(11):1492-1507. doi: 10.1158/2326-6066.CIR-23-1109 PMID: 38352574 Free PMC article. Updated. Preprint.
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Mol Cancer Ther. 2024 May 8:10.1158/1535-7163.MCT-23-0613. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38714351